SCHEMBL29933997

SCHEMBL29933997

COC(=O)c1ccc(C)c(CN(C)c2cncc(Br)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 1/20 0.43
▸ SMN1; SMN2 Q16637 6/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ HTT P42858 6/20 0.40
▸ MAPT P10636 2/20 0.40
▸ MAPK1 P28482 2/20 0.39
▸ ATM Q13315 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ TSHR P16473 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23501644 0.87 POLB (0.44) PKMSMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL29933872 0.87 POLB (0.44) PKMSMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL29933965 0.78 PKM (0.44) PKMSMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL23501668 0.78 PKM (0.44) PKMSMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL29934060 0.78 TAS1R3 (0.47) MEN1KMT2A
SCHEMBL17811367 0.71 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1HTTMAPTATM
SCHEMBL23501655 0.71 HDAC8 (0.48) PKMSMN1; SMN2ALDH1A1HTTMAPT
SCHEMBL23501616 0.71 PKM (0.52) PKMSMN1; SMN2HTTMAPTMAPK1
SCHEMBL31364809 0.71 PKM (0.52) PKMSMN1; SMN2HTTMAPTMAPK1
SCHEMBL29933845 0.71 PKM (0.52) PKMSMN1; SMN2HTTMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4516777-A2 COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR Nippon Shinyaku Co., Ltd. (JP) 2025-03-05 — — EP disclosed
CN-119371371-A Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2025-01-28 — — CN disclosed
CN-115315421-B Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2024-12-03 — — CN disclosed
US-20230101484-A1 COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR NIPPON SHINYAKU CO., LTD. (JP) 2023-03-30 — — US disclosed
CN-115315421-A Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2022-11-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230101484-A1 COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR PDGFRB, PDGFRA, PDGFA PKM 629/4885SMN1; SMN2 2679/4885ALDH1A1 2989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback